Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Delayed skeletal maturation, Birth length less than 3rd percentile, Small for gestational age, and Prominent forehead and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Head and neck | 2 | Relative macrocephaly, Triangular face |
HMGA2 encodes high mobility group AT-hook 2 (109 aa). Functions as a transcriptional regulator. Functions in cell cycle regulation through CCNA2. Plays an important role in chromosome condensation during the meiotic G2/M transition of spermatocytes. Highest expression in Cells Cultured fibroblasts (14.4 TPM) and Testis (1.3 TPM).
Silver-Russell syndrome 5 is caused by mutations in the HMGA2 gene on chromosome 12.
HMGA2 is classified as a druggable target (Clinically Actionable category) with score 0.0.
Consensus clinical diagnostic criteria for Silver-Russell syndrome (SRS) have been published .
SRS should be suspected in a proband with at least four of the following NH-CSS clinical criteria :
Source: GeneReviews — "Silver-Russell Syndrome"
No approved treatments are currently available for Silver-Russell syndrome 5. The disease remains an area of unmet medical need.
International consensus management guidelines for Silver-Russell Syndrome (SRS) have been published .
To establish the extent of disease and needs in an individual diagnosed with SRS, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Surveillance guidelines for children with SRS are outlined in . Table 7. Silver-Russell Syndrome: Recommended Surveillance
System/Concern |
|---|
No clinical trials have been registered for Silver-Russell syndrome 5.
37 publications have been identified in PubMed for Silver-Russell syndrome 5. Research spans Epidemiology / Natural History (27%), Case Report / Case Series (24%), and Basic Science / Preclinical (19%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 10 | 27% |
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 7:17 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Silver-Russell syndrome 5
1 |
Delayed skeletal maturation |
Digestive system | 1 | Feeding difficulties in infancy |
Growth and development | 1 | Intrauterine growth retardation |
Age of onset: before birth, at birth, infancy.
Silver-Russell Syndrome (SRS) is characterized by intrauterine growth restriction resulting in affected individuals being born small for gestational age with relative macrocephaly (head circumference ≥1.5 standard deviations [SD] above birth weight and/or length), a prominent forehead usually with frontal bossing, and frequently body asymmetry. This is followed by postnatal growth failure and, in some individuals, progressive limb length discrepancy and severe feeding difficulties in the first few years of life. Additional clinical features include triangular facies, fifth finger clinodactyly, and micrognathia with a small chin. Except for the limb length asymmetry, growth failure is usually proportionate but with normal head growth. The average adult height in untreated individuals is ~3.1±1.4 SD below the mean. To date, more than 1,000 individuals have been diagnosed with SRS [, , , , ]. The following description of the phenotypic features associated with this condition is based on these reports. Table 2. Silver-Russell Syndrome: Frequency of Select Features
Feature | % of Persons w/Feature | Comment |
|---|---|---|
Growth abnormalities | ≥80% | Incl prenatal or postnatal growth failure, relative macrocephaly, /or body asymmetry |
Feeding difficulties | 84%-100% | Or BMI ≤2SD at age 24 mos; or current use of a feeding tube or cyproheptadine for appetite stimulation |
Skeletal features | 75% | Incl hypoplastic elbow joints, fifth finger clinodactyly, joint contractures, brachydactyly, /or scoliosis |
Body asymmetry | 68% | Limb /or facial asymmetry |
Dysmorphic skin features | ≥64% | Incl triangular-shaped face, frontal bossing /or prominent forehead, micrognathia, downturned corners of mouth, dental crowding, shoulder dimples, caf au lait macules |
Craniofacial anomalies | 64% | Incl Pierre Robin sequence, cleft palate, /or dental anomalies |
Developmental delays | Global delays | 20%-65% |
Speech delays | 39%-50% | — |
Reduced muscle mass | 56% | — |
High-pitched voice | 45% | — |
Delayed close of anterior fontanelle | 43% | — |
Genitourinary abnormalities | 40% (in males) | Incl hypospadias /or cryptorchidism, renal anomalies (renal anomalies seen in 10%, primarily in upd(7)mat) |
Fasting hypoglycemia | 24%-29% | Excessive sweating w/ or w/o hypoglycemia has been reported in up to 67% of affected persons. |
Heart defects | 9% | Ventricular septal defects, atrial septal defects, patent ductus arteriosus Growth. The earliest manifestation of SRS is abnormal growth. Most children are born small for gestational age with birth weight and/or length two or more SD below the mean. |
Source: GeneReviews — "Silver-Russell Syndrome"
Several genotype-phenotype correlations have been observed in individuals with SRS. Using methylation-sensitive restriction enzymes to measure the degree of methylation of H19 within the 11p15.5 region, developed a scale of extreme H19 hypomethylation, moderate H19 hypomethylation, normal H19 methylation, and upd(7)mat (normal H19 methylation). They determined that children with SRS with extreme H19 hypomethylation (i.e., ≥6 SD below the mean or 9% methylation) were more likely to have more severe skeletal manifestations (including radiohumeral dislocation, syndactyly, greater limb asymmetry, and scoliosis) than children with SRS with moderate hypomethylation and those with upd(7)mat. A study by compared clinical features of children with SRS caused by 11p15.
Source: GeneReviews — "Silver-Russell Syndrome"
Penetrance for SRS is estimated to be 100% for males and females. Sex-limited penetrance is observed in individuals with CDKN1C- or IGF2-related SRS.
Source: GeneReviews — "Silver-Russell Syndrome"
Intrauterine growth restriction and short stature. The differential diagnosis of Silver-Russell syndrome (SRS) includes any condition that can cause intrauterine growth restriction and short stature. The presence of disproportionate short stature excludes the diagnosis of SRS and suggests a diagnosis of skeletal dysplasia. A skeletal survey can be performed to exclude a skeletal dysplasia that may mimic SRS. Note: Bone age may be delayed in children with SRS; however, delayed bone age is a nonspecific finding frequently seen in children with intrauterine growth restriction of many etiologies. Microcephaly. Individuals with SRS have a normal head circumference or relative macrocephaly. The presence of significant microcephaly should prompt a search for an alternative etiology. Disorders with intrauterine growth restriction and poor postnatal growth of interest in the differential diagnosis of SRS are listed in and . Table 4a. Monogenic Disorders with IUGR and Poor Postnatal Growth to Consider in the Differential Diagnosis of Silver-Russell Syndrome
Gene(s) | Disorder | MOI | Characteristic Features of Disorder |
|---|---|---|---|
Bloom syndrome | AR | Caf au lait macules | Abnormal sister chromatid exchange; Microcephaly BRCA1 BRCA2 BRIP1 ERCC4 FAAP100 FANCA FANCB FANCC FANCD2 FANCE FANCF FANCG FANCI FANCL FANCM MAD2L2 PALB2 RAD51 RAD51C RFWD3 SLX4 UBE2T XRCC2 |
Fanconi anemia | ARADXL | Caf au lait macules | chromosome breakage; Absent thumb(s) or thumb hypoplasia; Microcephaly; Radial anomalies; malignancy risk CCDC8 CUL7 OBSL1 |
Three M syndrome | AR | Fifth finger clinodactyly; Relatively large head; Triangular facies | Short broad neck; No limb or facial asymmetry CDC45 CDC6 CDT1 GMNN MCM5 ORC1 ORC4 |
ORC6 | Meier-Gorlin syndrome (OMIM PS224690) | ARAD | Frontal bossing; Small mouth |
IMAGe syndrome | AD1 | Frontal bossing; Genital abnormalities | Adrenal hypoplasia; Adrenal insufficiency; Metaphyseal dysplasia COL1A1 |
COL1A2 | COL1A1/2 osteogenesis imperfecta (OI)2 | AD | Blue sclerae; Relatively large head; Triangular face; Extremely delayed growth in progressively deforming OI |
Warsaw syndrome | AR | Fifth finger clinodactyly | chromosome breakage; Hearing loss; Microcephaly |
IGF1R | Insulin growth factor 1 resistance (incl deletion of 15q26.1)3 | ARAD | Clinodactyly; Dental anomalies |
Nijmegen breakage syndrome | AR | Chromosome instability; Microcephaly; Sloping forehead PCNT | Microcephalic osteo dysplastic primordial dwarfism t... |
Source: GeneReviews — "Silver-Russell Syndrome"
Genetic testing for HMGA2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Silver-Russell syndrome 5 has been reported in the published literature.
Silver-Russell Syndrome: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Assessment plotting of growth on age-appropriate growth curves | See MAGIC Foundation for SRS-specific growth charts.
| Eval by endocrinologist for GH deficiency, hypoglycemia, precocious or early-onset puberty | Referral to endocrinologist is recommended as soon as diagnosis of SRS is suspected or made.
| Consultation w/pediatric gastroenterologist dietician/nutritionist | • For children suspected of having GERD, eval for esophagitis incl video swallow studies, gastric emptying studies, pH probe, endoscopy are recommended.
Intestinal malrotation has been reported needs to be ruled out in those w/feeding disorders, constipation, delayed gastric emptying.
| Physical exam for eval of possible limb length asymmetry scoliosis. |
| • Physical exam for cleft palate bifid uvula w/submucous cleft palate
Referral to craniofacial center for further eval mgmt
|
| Eval of possible hypospadias /or cryptorchidism |
| Clinical exam for cardiac murmur or...
Source: GeneReviews — "Silver-Russell Syndrome"
Avoid prolonged fasting in infants and young children because of the risk of inducing hypoglycemia. For this reason, testing for GH deficiency by fasting is contraindicated . Avoid elective surgery whenever possible. If surgery is unavoidable, physicians must be aware of the risk for hypoglycemia, hypothermia, difficult healing, and difficult intubation (due to abnormal tooth distribution and micrognathia, which can affect airway visualization and the intubation process).
Source: GeneReviews — "Silver-Russell Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Silver-Russell Syndrome"
View trials for Silver-Russell syndrome 5
Evaluation
Frequency |
|---|
Growth | Measurement of growth parameters w/special attention to growth velocity weight gain | At each visit |
Genitourinary | Monitor for cryptorchidism | At each visit in infancy |
Family/Community | Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning). | At each visit GH = growth hormone; GI = gastrointestinal; OT = occupational therapy; PT = physical therapy |
Source: GeneReviews — "Silver-Russell Syndrome"
Phenotype severity distribution: 8 always present features.
Patient case studies
9 |
24% |
Laboratory research | 7 | 19% |
Clinical study results | 4 | 11% |
Testing and diagnosis research | 3 | 8% |
Research summaries | 3 | 8% |
New treatment approaches | 1 | 3% |
Świąder-Leśniak A (2026). [PMID: 42163355](https://pubmed.ncbi.nlm.nih.gov/42163355/). *Orphanet J Rare Dis*. [Epidemiology / Natural History]
Giabicani E (2026). [PMID: 40827087](https://pubmed.ncbi.nlm.nih.gov/40827087/). *J Clin Endocrinol Metab*. [Clinical Trial Publication]
Skaf K (2026). [PMID: 41727682](https://pubmed.ncbi.nlm.nih.gov/41727682/). *Front Endocrinol (Lausanne)*. [Basic Science / Preclinical]
Lee W (2026). [PMID: 41913935](https://pubmed.ncbi.nlm.nih.gov/41913935/). *J Child Orthop*. [Clinical Trial Publication]
Betoko RM (2026). [PMID: 42237104](https://pubmed.ncbi.nlm.nih.gov/42237104/). *BMC Pediatr*. [Case Report / Case Series]
Zhang L (2026). [PMID: 41918381](https://pubmed.ncbi.nlm.nih.gov/41918381/). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. [Clinical Trial Publication]
Tkemladze T (2026). [PMID: 41044236](https://pubmed.ncbi.nlm.nih.gov/41044236/). *Eur J Hum Genet*. [Diagnostic / Biomarker]
Licata AM (2026). [PMID: 41528113](https://pubmed.ncbi.nlm.nih.gov/41528113/). *Clin Genet*. [Review / Meta-Analysis]
Perriere A (2026). [PMID: 41697933](https://pubmed.ncbi.nlm.nih.gov/41697933/). *Horm Res Paediatr*. [Clinical Trial Publication]
Wang C (2026). [PMID: 41840691](https://pubmed.ncbi.nlm.nih.gov/41840691/). *Hum Genomics*. [Basic Science / Preclinical]